Design Therapeutics, Inc. - Common Stock, $0.0001 par value per share (DSGN)

CUSIP: 25056L103

Q4 2024 13F Holders as of 31 Dec 2024

Type / Class
Equity / Common Stock, $0.0001 par value per share
Shares outstanding
61,756,000
Total 13F shares
33,460,789
Share change
+1,417,939
Total reported value
$206,451,772
Put/Call ratio
57%
Price per share
$6.17
Number of holders
94
Value change
+$9,368,489
Number of buys
46
Number of sells
39

Quarterly Holders Quick Answers

What is CUSIP 25056L103?
CUSIP 25056L103 identifies DSGN - Design Therapeutics, Inc. - Common Stock, $0.0001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Design Therapeutics, Inc. - Common Stock, $0.0001 par value per share (DSGN) as of Q4 2024

As of 31 Dec 2024, Design Therapeutics, Inc. - Common Stock, $0.0001 par value per share (DSGN) was held by 94 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 33,460,789 shares. The largest 10 holders included SR One Capital Management, LP, Logos Global Management LP, BlackRock, Inc., Frazier Life Sciences Management, L.P., Point72 Asset Management, L.P., BAKER BROS. ADVISORS LP, TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, Almitas Capital LLC, and CITADEL ADVISORS LLC. This page lists 94 institutional shareholders reporting positions in this security for the Q4 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.